ARYx Therapeutics, Inc.
ARYX · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $829 | $1,004 | $2,242 | $2,986 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,316 | $2,238 | $3,777 | $2,335 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,145 | $3,242 | $6,019 | $5,321 |
| Operating Income | -$2,145 | -$3,242 | -$6,019 | -$5,321 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $369 | $394 | $371 | $466 |
| Net Income | -$2,514 | -$3,636 | -$6,390 | -$5,787 |
| % Margin | – | – | – | – |
| EPS | -0.075 | -0.11 | -0.22 | -0.21 |
| % Growth | 31.7% | 50% | -4.8% | – |
| EPS Diluted | -0.075 | -0.11 | -0.22 | -0.21 |
| Weighted Avg Shares Out | 33,458 | 33,456 | 29,349 | 27,591 |
| Weighted Avg Shares Out Dil | 33,458 | 33,456 | 29,349 | 27,591 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $5 | $63 | $12 |
| Interest Expense | $375 | $389 | $434 | $492 |
| Depreciation & Amortization | $206 | $231 | $251 | $261 |
| EBITDA | -$1,939 | -$3,011 | -$5,768 | -$5,060 |
| % Margin | – | – | – | – |